Literature DB >> 2709678

Metabolic clearance rate and production rate of calcitriol in uremia.

A Dusso1, S Lopez-Hilker, J Lewis-Finch, P Grooms, A Brown, K Martin, E Slatopolsky.   

Abstract

We have previously demonstrated that while both normal humans and dogs tightly control serum calcitriol levels after 25(OH)D administration, anephric humans and 5/6 nephrectomized dogs significantly increase circulating 1,25(OH)2D when supraphysiological concentrations of 25(OH)D are reached in serum. Plasma 1,25(OH)2D level is determined not only by its rate of production but also by its rate of degradation. To further characterize the mechanisms involved in the responses to 25(OH)D therapy in normal circumstances and in chronic uremia, we measured metabolic clearance rate (MCR) and production rate (PR) of 1,25(OH)2D in normal dogs and in dogs with moderate and severe renal failure, at normal and supraphysiological serum concentrations of 25(OH)D. Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively). Oral 25(OH)D administration for two weeks did not affect MCR either in normal animals or in both groups of uremic dogs. 25(OH)D treatment did not affect production rates in normal dogs and in animals with moderate renal failure (with normal basal values of 1,25(OH)2D), but significantly increased 1,25(OH)2D production from 0.13 +/- 0.01 to 0.25 +/- 0.04 micrograms/day (P less than 0.05) in dogs with severe renal insufficiency. These data suggest that it is the basal level of 1,25(OH)2D which regulates the synthesis of 1,25(OH)2D in response to 25(OH)D administration in normal and uremic animals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2709678     DOI: 10.1038/ki.1989.64

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Hyperphosphataemia in renal failure: causes, consequences and current management.

Authors:  Fouad Albaaj; Alastair Hutchison
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

Review 3.  Vitamin D and its analogs in chronic renal failure.

Authors:  E Slatopolsky; A J Brown
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 4.  The Impact of Chronic Kidney Disease on Nutritional Status and Its Possible Relation with Oral Diseases.

Authors:  Micaela Costacurta; Michele Basilicata; Giulia Marrone; Manuela Di Lauro; Vincenzo Campolattano; Patrizio Bollero; Raffaella Docimo; Nicola Di Daniele; Annalisa Noce
Journal:  Nutrients       Date:  2022-05-10       Impact factor: 6.706

Review 5.  Impaired vitamin D metabolism in CKD.

Authors:  Cortney Bosworth; Ian H de Boer
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

6.  Effects of Vitamin D2 Supplementation on Vitamin D3 Metabolism in Health and CKD.

Authors:  Zona Batacchi; Cassianne Robinson-Cohen; Andrew N Hoofnagle; Tamara Isakova; Bryan Kestenbaum; Kevin J Martin; Myles S Wolf; Ian H de Boer
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-02       Impact factor: 8.237

7.  Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials.

Authors:  Ian H de Boer; Michael C Sachs; Michel Chonchol; Jonathan Himmelfarb; Andrew N Hoofnagle; Joachim H Ix; Robin A Kremsdorf; Yvonne S Lin; Rajnish Mehrotra; Cassianne Robinson-Cohen; David S Siscovick; Michael W Steffes; Kenneth E Thummel; Russell P Tracy; Zhican Wang; Bryan Kestenbaum
Journal:  Am J Kidney Dis       Date:  2014-04-03       Impact factor: 8.860

Review 8.  Vitamin D in Chronic Kidney Disease and Dialysis Patients.

Authors:  Guillaume Jean; Jean Claude Souberbielle; Charles Chazot
Journal:  Nutrients       Date:  2017-03-25       Impact factor: 5.717

Review 9.  Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease.

Authors:  Joao F de Brito Galvao; Larry A Nagode; Patricia A Schenck; Dennis J Chew
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2013 Mar-Apr
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.